

Challenges in Prescribing PCSK9 Inhibitors



SURVEY FINDINGS

WHAT

The National Lipid Association developed a 170-question online survey to collect and study healthcare providers' experiences around the Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.

WHEN

August 26 through
October 14, 2016



WHO

434

Providers and personnel
working with patients that
have lipid disorders*

370

Respondents prescribe
medication

60%

Of respondents have
been in their position
more than 11 years

80%

Of respondents see more
than 25 patients requiring
drug therapy for lipid
disorders per month

WHAT WE FOUND

96%

Of respondents with patients with atherosclerotic cardiovascular disease (ASCVD) have had initial denials on PCSK9 inhibitor prescriptions

97%

Of respondents take further action after getting a denial for a PCSK9 inhibitor prescription



**ONLY
43%**

Of respondents were successful, after all appeals, in attaining approval 75% or more of the time for their patients with Familial Hypercholesterolemia (FH)

**ONLY
36%**

Of respondents were successful, after all appeals, in attaining approval 75% or more of the time for their patients with ASCVD

70%

Of respondents wait more than 30 days from time of writing the PCSK9 inhibitor prescription to fulfillment of first prescription for their patients with FH

50%

Of respondents spend more than 1 hour per week on each patient's prior authorization

**Respondents received no compensation for participation.*